RBC Capital increases Stryker price target to $120 — 5 key facts

RBC Capital increased its price target on Stryker shares from $108 to $120, according to Web Breaking News.

Advertisement

Here are five key facts:

 

1. RBC Capital has an “outperform” rating on Stryker shares.

 

2. Stryker has a market cap of $40.84 billion.

 

2. The P/E ratio is 28.97.

 

4. The company’s 52-week low is $86.68 and 52-week high is $113.85.

 

5. For the first quarter of 2016, Stryker reported net earnings reaching $402 million, up $79.5 million in the first quarter the year prior.

 

More device news:
Stryker’s net earnings up 79.5%; Orthopedics sales reach $1.1B: 9 key notes on Q1 2016
FDA clears Exatech’s Vantage Total Ankle — 5 highlights
Medtech’s ROSA system to be featured at AANS annual meeting — 3 quick notes

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

  • From new technology acquisitions to regulatory clearances to leadership changes, here are 20 developments and updates from the biggest players…

  • SurGenTec’s ION-C earned FDA 510(k) clearance for ION-C navigation instruments with the ION-C posterior cervical facet fixation implant, according to…

  • VB Spine has made big pushes into the spine medtech space so far in 2026, including global expansions. Six headlines…

Advertisement

Comments are closed.